Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors.
about
Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain managementSingle cycle structure-based humanization of an anti-nerve growth factor therapeutic antibodyCharacterization of neutralizing affinity-matured human respiratory syncytial virus F binding antibodies in the sub-picomolar affinity range.Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.Potential mechanisms for hypoalgesia induced by anti-nerve growth factor immunoglobulin are identified using autoimmune nerve growth factor deprivation.Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis.Monoclonal antibodies for the treatment of osteoarthritis.Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.Mechanisms of Ricin Toxin Neutralization Revealed through Engineered Homodimeric and Heterodimeric Camelid Antibodies.The monoclonal S9.6 antibody exhibits highly variable binding affinities towards different R-loop sequences.Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.A model for regulation by SynGAP-α1 of binding of synaptic proteins to PDZ-domain 'Slots' in the postsynaptic densityStructural characterization of nonactive site, TrkA-selective kinase inhibitors.Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model.Nerve growth factor signaling in prostate health and disease.Perineural invasion and associated pain in pancreatic cancer.Anti-nerve growth factor therapy increases spontaneous day/night activity in mice with orthopedic surgery-induced pain.The use of TrkA-PathHunter assay in high-throughput screening to identify compounds that affect nerve growth factor signaling.Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain.Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology.Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease.High throughput solution-based measurement of antibody-antigen affinity and epitope binning.An automated immunoassay for early specificity profiling of antibodiesSystems Pharmacology of the NGF Signaling Through p75 and TrkA Receptors.NGF - the TrkA to successful pain treatmentMorphologic, stereologic, and morphometric evaluation of the nervous system in young cynomolgus monkeys (Macaca fascicularis) following maternal administration of tanezumab, a monoclonal antibody to nerve growth factor.Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.Equilibrium and kinetic analysis of human interleukin-13 and IL-13 receptor alpha-2 complex formation.[EXPRESS] Monoclonal antibodies for chronic pain: a practical review of mechanisms and clinical applications.Strategies Using Bio-Layer Interferometry Biosensor Technology for Vaccine Research and Development.Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis.Tanezumab: a selective humanized mAb for chronic lower back pain.Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis.Influence of nerve growth factor in endometriosis-associated symptoms.First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain.
P2860
Q27011486-06782180-C5A1-4C4A-9829-098A1C6DF677Q28731515-12B21032-DAC7-4B46-A444-4312600EA8E9Q34191108-6195D6BD-6B9D-43E8-9677-388DE314C146Q34336925-1EC4D82A-124C-4EEA-BB87-B7BD757FE11DQ35463321-638A3CB5-11F8-483D-B32E-063291966EBEQ36050186-39388D40-99CE-45F4-BFB0-A7FA974CFFF6Q36113839-EB437DA0-21BA-46DA-B090-FDB7508A4188Q36236043-3F7D3414-61D9-44B3-BE72-2B6079F6736EQ36282935-02DAF7BC-7BCD-47FE-A5C6-85DA640A174DQ36396026-852CB9F6-F462-4932-A4FC-9BE18BE01A89Q36706795-BF70062B-BE7D-4AAF-95D5-135737E6E21AQ37292998-A8DA4AA8-C7C4-42AB-95E9-9EF1438A40FAQ37599025-411C3358-CF0C-4497-B58A-6C10E4F7048EQ37604491-1BBEE87B-16DB-44F3-BF0D-2894CE050374Q37694590-71AC72CB-BACD-4368-9056-5C1F4490823AQ37937421-BE4FA7AC-D115-4F47-A0F2-807B27F9712DQ38903010-8DBDDC4D-16A4-4DA3-918A-89E1FD96F073Q39185655-7A462343-12B3-45DC-A0B7-442B558A22CAQ39195605-2A631771-6B5B-4E60-B8ED-77EA04B9D734Q39210251-FD62B852-4F65-4CAC-9B79-E9E152F4A806Q40186234-906B5DFB-AC86-47E5-B6CD-133E78626F7DQ41642900-8E0E1F6A-10C9-4532-AF35-4F30AC96AF08Q41810948-61DE04EC-9499-4A22-9B20-4287C84FC27AQ41874335-2A67804F-FCED-4613-BC2D-32F35C5ACB3FQ42110905-76DD8D89-56DE-4503-BB84-3531AC4DACC1Q42325445-AB89BD45-B992-4DE0-9A69-5CD93687DC64Q42467356-6F7E8B95-C196-4E93-A37C-52854F69A6D9Q43525106-224FD382-F84F-434B-BB3F-0B413BF2E63BQ45354358-FE038EC5-0DB4-46F7-8DD6-B2E28E5D4EBEQ46156381-10C5D6B0-DCE6-4207-9433-4F1C6E690410Q47171892-F85720A2-1EC7-4067-B904-9A8A5DDE8D53Q49402122-E62720DC-3498-4EDA-A3A8-587D6A1E1AF5Q51765862-A6967AAD-9F4C-423F-A99D-B490CAE28568Q52593024-47568128-8FA6-4ACC-8DE2-B84736653918Q54500961-D5952EEA-BE6C-467C-A7FA-54DB543F2DF9Q55264146-3F6EE2AA-95FA-4967-9DB3-79614DC586FA
P2860
Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Probing the binding mechanism ...... ng a repertoire of biosensors.
@en
type
label
Probing the binding mechanism ...... ng a repertoire of biosensors.
@en
prefLabel
Probing the binding mechanism ...... ng a repertoire of biosensors.
@en
P2093
P2860
P356
P1433
P1476
Probing the binding mechanism ...... ng a repertoire of biosensors.
@en
P2093
Dan Stephen Malashock
Jaume Pons
Yasmina Noubia Abdiche
P2860
P304
P356
10.1110/PS.035402.108
P577
2008-05-27T00:00:00Z